NeoGenomics(NEO) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NEO NeoGenomics

Watchlist

9.825
+0.305+3.20%

Close Mar 14 16:00 ET

9.825
0.0000.00%

Post 20:01 ET

1.26BMarket Cap-15.85P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

William Blair Initiates NeoGenomics(NEO.US) With Buy Rating
Moomoo NewsMar 10 11:32 ET · Ratings
NeoGenomics' Strategic Acquisition of Pathline: A Low-Risk Investment for Market Expansion and Growth
TipRanksMar 10 11:15 ET
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Moomoo NewsMar 10 09:33 ET · Ratings
NeoGenomics (NEO) Gets a Buy From Craig-Hallum
TipRanksMar 10 09:06 ET · Ratings
NeoGenomics Expects Deal Accretive to Adj EBITDA Starting 2026 >NEO
Dow JonesMar 10 07:03 ET
Express News | Neogenomics Expands Oncology Testing Reach in the Northeast With Acquisition of Pathline
ReutersMar 10 07:00 ET

Comments

Teddy123

Mar 10 19:22

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

$NeoGenomics (NEO.US)$
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

Kevin Travers

Feb 19 05:27

Columns Wall Street Today: S&P 500 Hits Record To Start Short Week

Overall, the market began to climb after a very slow start. Less than two hours ago, the market was down 25 bps, before a last ten-minute sprint sent equities climbing, with a record close and price for the S&P 500
Just past 4 pm ET, the $S&P 500 Index (.SPX.US)$ climbed 0.24%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 0.02%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.07%.
MACRO
In macro news, watch fo...

Live Stock Financial Podcast. What are you watching on the market?

Stock_Drift

Sep 24, 2024 07:24

$NeoGenomics (NEO.US)$

Stock_Drift

Sep 24, 2024 06:48

$NeoGenomics (NEO.US)$

Moomoo AI

Feb 29, 2024 21:27

The company's debt usage, EBIT loss, and liabilities exceeding cash and short-term receivables are worrisome. Its slow revenue growth and weak balance sheet position add to its perceived riskiness.

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NEO NeoGenomics

Trade Overview

Capital Trend

News

Comments

Trending Stocks